<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Treatment of central <z:mp ids='MP_0008912'>nervous</z:mp> system relapse in adult <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> is a challenge and outcome is poor </plain></SENT>
<SENT sid="1" pm="."><plain>Liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> has a prolonged half-life and, given intrathecally, has produced high response rates in patients with central <z:mp ids='MP_0008912'>nervous</z:mp> system relapse of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to evaluate the efficacy and tolerability of liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> in central <z:mp ids='MP_0008912'>nervous</z:mp> system relapse of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> or Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN AND METHODS: Liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (50 mg) was given intrathecally together with systemic or intrathecal <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> once every 2 weeks in a phase II European trial </plain></SENT>
<SENT sid="4" pm="."><plain>The primary end-point, cytological response in the cerebrospinal fluid after one or two cycles, was evaluated at the time of next treatment </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Nineteen heavily pretreated patients (median age, 53 years; range 24-76 years) were evaluable: 14 with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> and 5 with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>Complete cytological remission as best response after two cycles of liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> was confirmed in 74% of the patients: 86% of those with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> and 40% of those with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>Nine of the 14 patients who achieved complete remission relapsed after a median of 7 months </plain></SENT>
<SENT sid="8" pm="."><plain>The median overall survival was 11 months </plain></SENT>
<SENT sid="9" pm="."><plain>Adverse events were observed in 89% of the patients (57% of cycles) </plain></SENT>
<SENT sid="10" pm="."><plain>Grade III-IV events with potential correlation to liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> occurred in 32% of the patients </plain></SENT>
<SENT sid="11" pm="."><plain>The most frequent adverse event was <z:hpo ids='HP_0002315'>headache</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>One patient developed severe neurological complications with <z:hpo ids='HP_0000572'>loss of vision</z:hpo> and a conus syndrome </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Overall, liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> showed excellent antileukemic activity </plain></SENT>
<SENT sid="14" pm="."><plain>Toxicity was acceptable but appeared to increase with the number of cycles </plain></SENT>
<SENT sid="15" pm="."><plain>Future evaluation in prophylaxis is of interest </plain></SENT>
</text></document>